Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

836
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
836

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Journal of the National Cancer Institute·2026
Same author

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

British journal of cancer·2026
Same author

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

JAMA oncology·2025
Same author

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Diagnosis of Oral Cancer With Deep Learning. A Comparative Test Accuracy Systematic Review.

Oral diseases·2025
Same author

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: May 4, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.9K

Molecular testing in breast cancer.

Costanza Paoletti1, Daniel F Hayes

  • 1Breast Oncology Program of the Comprehensive Cancer Center, and the Department of Internal Medicine, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109;

Annual Review of Medicine
|January 16, 2014
PubMed
Summary

Tumor biomarker tests are essential for personalized breast cancer medicine. While some biomarkers exist for risk, prognosis, and monitoring, more research is needed to identify new tests for better patient treatment.

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.6K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

12.6K

Related Experiment Videos

Last Updated: May 4, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.9K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.6K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

12.6K

Area of Science:

  • Oncology
  • Genetics
  • Medical Diagnostics

Background:

  • Personalized medicine in breast cancer relies heavily on tumor biomarker tests.
  • High analytical validity and clinical utility are essential for guiding patient care.
  • Currently, only a limited number of tumor biomarkers meet these stringent standards.

Purpose of the Study:

  • To review the current status and challenges of tumor biomarker tests in breast cancer.
  • To highlight existing biomarkers and their applications.
  • To emphasize the need for further research in biomarker discovery.

Main Methods:

  • Review of existing literature on tumor biomarker tests for breast cancer.
  • Identification of validated biomarkers for risk assessment, prognosis, and monitoring.
  • Discussion of ongoing research efforts and future directions.

Main Results:

  • Germline DNA single-nucleotide polymorphisms in BRCA1 and BRCA2 genes are used for high-risk assessment in unaffected women.
  • Tissue-based markers aid in determining prognosis and predicting therapy response.
  • Circulating markers like MUC1, CEA, and tumor cells assist in monitoring metastatic disease.
  • Biomarkers for predicting therapeutic toxicity are still under development.

Conclusions:

  • The number of clinically validated tumor biomarker tests for breast cancer is limited.
  • Further research is crucial to expand the availability of reliable biomarker tests.
  • Enhancing biomarker discovery will enable more precise and timely treatment for breast cancer patients.